ArticleMolecular cancer therapeutics2017

TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.

Nagako Akeno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.